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Poster Session II S375Materials andMethods:Three humanMSCs cultures fromdifferent
healthy donors & 5 neuroblastoma cell lines (BE2c, BE2M17, IMR32,
SK-N-LP and SH-SY5Y) originally derived frommetastatic sites were
used. ELISA was used to determine the concentration of SDF-1 re-
leased by MSCs in conditioned culture medium. CXCR4 and
CXCR7 expression on neuroblastoma cells was determined by flow cy-
tometer. shRNA plasmid transfection was used to establish stable
CXCR4 andCXCR7 knockdown IMR32 cell lines and assessed the re-
spective functionsof these two receptorsonneuroblastomacells.Trans-
well migration assay, invasion and adhesion assays were utilized to test
the migration, invasion and adhesion efficiency of normal or knock-
down neuroblastoma cells towards MSCs under the influence of
MSCs conditionedmedium, SDF-1 or AMD3100 (CXCR4 inhibitor).
Results: SDF-1 was secreted by all human bone marrow derived
MSCs. CXCR4 and CXCR7 were expressed on neuroblastoma cells
surface. Themigration of IMR32, SK-N-LP and SH-SY5Ywas dra-
matically enhanced under treatments with culture medium from
MSCs. The migration ability of CXCR4 knock down (IMR32-sh-
CXCR4) but not CXCR7 knock down (IMR32-sh-CXCR7) was
partially blocked under culture medium of MSCs and SDF-1. In
contrary, all migration could be blocked by AMD3100. The invasion
ability of IMR32-sh-CXCR4 but not IMR32-sh-CXCR7 was sup-
pressed when treated with either culture medium of MSCs or
SDF-1. All invasion activity could be blocked byAMD3100, suggest-
ing such effect was associated with SDF-1/CXCR4 axis.
Conclusion: Our data suggested that: 1) SDF-1 was secreted by
MSCs; 2) metastatic neuroblastoma cell lines expressed both
CXCR4 and CXCR7, and the interactions of these receptors with
SDF-1 secreted by MSCs may play an important role in the migra-
tion, invasion but not adhesion in the metastasis of neuroblastoma
to bone marrow.PHARMACY465
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Granulocyte colony stimulating factor (G-CSF) has been widely
used to accelerate neutrophil recovery following hematopoietic
stem cell transplantation (HSCT). BMT practice has shifted from
introducing G-CSF immediately after HSCT to delaying its initia-
tion until 5-7 days after the HSCT. The primary reason for this
change in practice is not only for pharmacoeconomic consideration,
but also for its preferential pharmacologic effect as it takes about 7
days for immature pluripotent stem cells to differentiate into highly
G-CSF responsible neutrophilic progenitor cells. In April 2010, we
implemented a practice change from initiating G-CSF support from
day 0 (immediately after stem cell infusion) to day +5 for autologous
SCT (ASCT) and day +7 for allogeneic SCT (AlloSCT).
A single-center retrospective study was performed, between Janu-
ary 2010 to August 2010, in a total of 60 patients who received G-
CSF support followingHSCT; of these patients, 30 patients received
early G-CSF and 30 patients received delayed G-CSF. G-CSF ther-
apy was administered intravenously at a dosage of 5mcg/kg/day. Pri-
mary objective of the study was to assess cost analysis of early and
delayed G-CSF therapy in patients who underwent HSCT.
Comparedwith the early G-CSF group, delayedG-CSF group re-
quired fewer number of G-CSF doses per patient (median, 7 doses
vs. 13 doses, p\0.001). The median acquisition cost of G-CSF per
patient was $3,300 in the early G-CSF group and $1,800 in the de-
layed G-CSF group, with total cost savings of $240,000 per year.
The median time to neutrophil engraftment in the early G-CSF
group was a day shorter compared to delayed G-CSF group (11
days vs. 12 days; p\0.05). However, there were no differences be-
tween the early and delayed G-CSF groups in the median duration
of neutropenia (6.5 days vs. 7 days; p 5 NS), rate of febrile neutro-
penia (60.9% vs. 54.1%; p5NS), median duration of febrile neutro-
penia (1 day vs. 1 day; p 5 NS), and median length of hospital stay
(15.5 days vs.15 days; p 5 NS).Delaying G-CSF support from day 0 to day +5 for ASCT and day
+7 for AlloSCT is a cost-effective strategy inHSCTpatients without
any significant impact on the duration of neutropenia and/or dura-
tion of hospitalization.
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STANDARDIZATION OF MELPHALAN ADMINISTRATION
Davis, D., Shapiro, J., Wetzstein, G. Moffitt Cancer Center, Tampa, FL
Over the past several years drug shortages have become a larger
problem for hospitals, medical professionals and ultimately a crisis
for patients who are directly affected. The American Hospital Asso-
ciation reports that 82% of their members this year have been af-
fected by some form of drug shortage. As of September 2011 the
FDA currently reports 71 medications listed as shortage status.
Melphalan is a very potent alkylating chemotherapy agent that is
part of conditioning chemotherapy for patients with either multiple
myeloma who will have a high-dose melphalan regimen or lym-
phoma patients receiving the BEAM regimen (BCNU, etoposide,
cytarabine, melphalan) prior to undergoing an autologous stem
cell transplant. Melphalan is unique in that it has an extremely short
stability requiring rapid administration after preparation. Preparing
this medication in a timely fashion is essential for drug efficacy and
can be burdensome for nursing and pharmacy staff.
In order to prevent medication shortages and reduce preparation
redundancies, the BMTpharmacists developed a plan to improve co-
ordination and efficiency of melphalan utilization. This was accom-
plished by standardizing times of administration for melphalan to
only be administered twice a day. This involved process changes
for BMT nursing and pharmacy. The nurses in BMT would give
the clinical leader the ok to proceed with chemotherapy. Once all pa-
tients were given the ok to proceed the floor clinical leader would
contact the pharmacist to make the chemotherapy immediately.
This process change went into effect October 19th, 2010 at Moffitt
Cancer Center.
This process change was retrospectively evaluated from January 1
to August 31, 2011. During this time period, 52 vials of melphalan
were saved which resulted in a cost savings of $88,137 in drug cost
alone and no patients were affected in May 2011 during a temporary
melphalan drug shortage.
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OBSERVATIONAL STUDY OF TACROLIMUS-INDUCED POSTERIOR RE-
VERSIBLE ENCEPHALOPATHY SYNDROME IN ALLOGENEIC STEM CELL
TRANSPLANTATION
Hammerstrom, A.E.1, Howell, J.E.1, Gulbis, A.M.1, Wilhelm, K.L.1,
Hart, J.W.1, Popat, U.R.2 1University of Texas MD Anderson Cancer
Center, Houston, TX; 2University of Texas MDAnderson Cancer Center,
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Objectives: Tacrolimus-induced posterior reversible encephalopa-
thy syndrome (PRES) is a potential complication of allogeneic hema-
topoietic stem cell transplantation (HSCT). Due to the paucity of
information on the management of PRES in HSCT patients receiv-
ing tacrolimus, this retrospective review will provide information on
trends associated with the incidence of PRES and characterize its
management.
Methods: A retrospective review was conducted of patients receiv-
ing tacrolimus for prevention of graft versus host disease (GVHD)
after allogeneic HSCT who developed PRES from 2008 to 2010 at
the University of Texas MD Anderson Cancer Center. Patients
were included if they were receiving tacrolimus at time of PRES di-
agnosis.
Results: Sixteen patients were identified as having PRES. Compared
to baseline, patients with PRES were likely to have an increase in
mean arterial pressure (MAP), weight, and serum creatinine. Ele-
vated tacrolimus levels and hypomagnesemia were not clearly ob-
served with PRES onset. When tacrolimus was held and then
restarted either at the same dose or targeting a lower therapeutic
level (n 5 9), 44% were alive at discharge. Of the patients switched
to another agent at time of PRES (n 5 2), 50% were alive at dis-
charge. In those patients in which tacrolimus was never held (n 5
5), 20% were alive at discharge.
Conclusions: The incidence of PRES at our institution from 2008-
2010 was 1.1%. A lower chance of survival was observed when tacro-
limus was never held during the PRES episode compared to the
